**DiaSorin and B·R·A·H·M·S, part of Thermo Fisher Scientific, partner to develop and commercialize the new LIAISON® B·R·A·H·M·S MR-proADM™: A new immunodiagnostic solution to improve patient care**

**Saluggia, May 9, 2022** - DiaSorin (FTSE MIB: DIA) and B·R·A·H·M·S GmbH, part of Thermo Fisher Scientific, announce the signature of a partnership aimed at the development and commercialization of the new LIAISON® B·R·A·H·M·S MR-proADM™ immunodiagnostic test. The test offers a more precise assessment of disease severity, will improve patient management and will be made initially available in countries accepting the CE Mark in Q1 2023, whereas the launch in the US is expected for the second half of 2024.

The new LIAISON® B·R·A·H·M·S MR-proADM™ is an automated in vitro chemiluminescent immunoassay (CLIA) intended for the quantitative determination of the MR-proADM biomarker in human plasma. MR-proADM is a biomarker released during inflammatory processes and infections. Supported by extensive literature and robust medical evidence MR-proADM can improve risk stratification and can support decision making on required level of care.

In conjunction with clinical assessment and other laboratory findings, the assay will aid in the diagnosis of a number of severe conditions such as sepsis and septic shock, lower tract respiratory infections, urinary tract infections and kidney disease.

Delayed treatment in patients presenting to the emergency department with a suspected infection may result in prolonged hospitalization, increased morbidity, and greater infection-related mortality in the presence of sepsis. An accurate clinical assessment, including possibly disease severity, is therefore crucial for personalized therapy setting, and for improving patient triage especially in high demand emergency cases.

The test is developed to run on the LIAISON® CLIA analyzer family and offers a highly automated solution to both the Emergency Department (ED) and Intensive Care Units (ICU). In the ED, MR-proADM can be used to support hospital admissions vs outpatient management decisions, as well aiding on intensity of care. In addition, in ICU the identification of clinically stable patients allows for de-escalation of the intensity of care and earlier discharge, eventually leading to more efficient utilization of critical care resources.

“We are proud to announce this new strategic partnership with B·R·A·H·M·S, part of Thermo Fisher Scientific, that confirms our ability to expand DiaSorin’s offering of innovative, specialty tests” commented Carlo Rosa, CEO of DiaSorin. “We are confident that the new test will support clinical decision making and critical care resources optimization, the latter made very relevant during the Covid-19 pandemic.”
About DiaSorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide. The Group operates in 5 continents through 43 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the “Diagnostic Specialist”. More info at www.diasoringroup.com